Evotec Se Adr Stock Current Liabilities
| EVO Stock | USD 4.70 0.03 0.64% |
Evotec SE ADR fundamentals help investors to digest information that contributes to Evotec SE's financial success or failures. It also enables traders to predict the movement of Evotec Stock. The fundamental analysis module provides a way to measure Evotec SE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evotec SE stock.
At this time, Evotec SE's Total Current Liabilities is very stable compared to the past year. As of the 12th of December 2024, Non Current Liabilities Total is likely to grow to about 750.3 M, while Non Current Liabilities Other is likely to drop about 808.7 K. Evotec | Current Liabilities |
Evotec SE ADR Company Current Liabilities Analysis
Evotec SE's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Evotec Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Evotec SE is extremely important. It helps to project a fair market value of Evotec Stock properly, considering its historical fundamentals such as Current Liabilities. Since Evotec SE's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evotec SE's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evotec SE's interrelated accounts and indicators.
Click cells to compare fundamentals
Evotec Current Liabilities Historical Pattern
Today, most investors in Evotec SE Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Evotec SE's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Evotec SE current liabilities as a starting point in their analysis.
Evotec SE Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Evotec Liabilities And Stockholders Equity
Liabilities And Stockholders Equity |
|
In accordance with the recently published financial statements, Evotec SE ADR has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Evotec Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evotec SE's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evotec SE could also be used in its relative valuation, which is a method of valuing Evotec SE by comparing valuation metrics of similar companies.Evotec SE is currently under evaluation in current liabilities category among its peers.
Evotec SE Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evotec SE from analyzing Evotec SE's financial statements. These drivers represent accounts that assess Evotec SE's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evotec SE's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.7B | 3.5B | 4.7B | 2.7B | 3.8B | 4.0B | |
| Enterprise Value | 2.7B | 3.6B | 4.7B | 2.8B | 3.9B | 4.1B |
Evotec SE ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evotec SE's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evotec SE's managers, analysts, and investors.Environmental | Governance | Social |
Evotec Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0177 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 355.11 M | ||||
| Shares Owned By Institutions | 2.19 % | ||||
| Number Of Shares Shorted | 401.56 K | ||||
| Price To Earning | 444.00 X | ||||
| Price To Book | 1.64 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 781.43 M | ||||
| Gross Profit | 151.54 M | ||||
| EBITDA | (7.16 M) | ||||
| Net Income | (83.91 M) | ||||
| Cash And Equivalents | 823.67 M | ||||
| Cash Per Share | 2.33 X | ||||
| Total Debt | 626.2 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 5.46 X | ||||
| Cash Flow From Operations | 33.95 M | ||||
| Short Ratio | 2.32 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Price To Earnings To Growth | 3.15 X | ||||
| Target Price | 6.2 | ||||
| Number Of Employees | 5.01 K | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 1.7 B | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | (476.29 M) | ||||
| Working Capital | 438.59 M | ||||
| Five Year Return | 4.88 % | ||||
| Net Asset | 2.3 B |
About Evotec SE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evotec SE ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evotec SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evotec SE ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving together with Evotec Stock
Moving against Evotec Stock
| 0.93 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.92 | LLY | Eli Lilly | PairCorr |
| 0.81 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.77 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Evotec SE Piotroski F Score and Evotec SE Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.